Asia Pacific In Situ Hybridization Market

APAC In Situ Hybridization Market Size (2022 to 2027)

The size of the Asia Pacific in Situ Hybridization Market was worth USD 147.27 million in 2022 and estimated to be growing at a CAGR of 5.95%, to reach USD 196.62 million by 2027.

Cancer is one of the significant driving forces for the APAC in situ hybridization market. Over the past decades, extensive studies related to human diseases such as cancer have been conducted, recognizing that recurrent genomic abnormalities are possible drivers of a variety of cancers. According to GLOBOCAN, in 2019, 44.2 million people had cancer and 9.7 million deaths from cancer. In addition, there were around 18.5 million new cases in 2019. Thus, cancer incidence could reach 29.7 million, with a death rate of 16.9 million by 2040. Other genetic disorders such as hemophilia, thalassemia and sickle cell anemia, etc., also increase steadily over time. According to research conducted, the incidence of hemophilia has tripled to 1,126,000, compared to previous estimates of 401,000. The countries most affected are India, China, Australia, and New Zealand. This increase is likely to pull the market during the projected period.

Several technological developments in cytogenetic assays enable researchers to develop, discover and implement novel diagnostic procedures for gene expression in situ at the RNA level. This will provide unique insight into the interaction between cancer cells and the tumor microenvironment as cancer progresses. In developed countries, high-quality molecular diagnostic tests are already available. The market is expected to be driven by the unmet demand in developing countries, including India and China, which offer significantly in situ hybridization opportunities. Other factors such as increasing geriatric populations, growing rate of infectious diseases and cancer, better ability to detect abnormalities related to congenital malformations or mental disorders, expansion of health care infrastructure, to study familial history, and increased investments by respective government agencies and key players in the region are responsible for expanding the APAC in situ hybridization market during the forecast period.

However, in situ hybridization is a technique-sensitive procedure; the inability of probes to detect target sequences after a few repetitions may not provide desired results, which may restrain the market. In addition, other factors such as the high cost of the probes, strict government regulations, and approval, the low detection capability of fluorescent in situ hybridization for significant patient abnormalities, the lack of a commercial market for diagnostic procedures, and the long-time taken for detection procedures are expected to hamper the APAC in situ hybridization market. These factors have resulted in the limited availability of diagnostic tests and their adaptability, especially in emerging economies.

This research report on APAC In situ hybridization market has been segmented and sub-segmented into the following categories.

By Technique:

• FISH
• CISH

By Application:

• Cancer Diagnosis
• Neuroscience
• Cytology
• Infectious Disease

By End User:

• Molecular Diagnostic Laboratories
• Academic and Research Institutions

By Type:

• DNA
• RNA

By Product:

• Instruments
• Probes & Kits

By Country:

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Geographically, the APAC region is expected to play a dominating role in the global in situ hybridization market during the forecast period due to the increasing incidence and diagnosis of cancer in Australia and China, attributed to the increase in clinical cancer research by biotechnology companies and pharmaceuticals, the increase in medical tourism, government initiatives and the increasing use of complementary diagnostics.

In Japan, the in-situ hybridization market is estimated to register a healthy CAGR during the forecast period. At the same time, China is projected to lead the regional market.

In terms of growth, Australia is the second-largest market for APAC in situ hybridization due to favorable government policies regarding the development of healthcare infrastructure, increased biomedical research activities dedicated to hybridization techniques, increased prevalence and diagnosis of cancer, the growing trend for a sedentary lifestyle and increased per capita spending. Other APAC regions will also support market growth attributed to economic growth and technological advancements in medicine and healthcare in South Korea, New Zealand, and the Philippines.

KEY MARKET PLAYERS:

A few of the notable companies operating in the APAC in situ hybridization market profiled in this report are Abbott Laboratories, Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Leica Biosystems Nussloch GmbH (Germany), Agilent Technologies (U.S.), Thermo Fisher Scientific, Inc. (U.S.), Merck KGaA (Germany), PerkinElmer, Inc. (U.S.), Exiqon A/S (Denmark), BioGenex Laboratories, Inc. (U.S.), Advanced Cell Diagnostics, Inc. (U.S.), and Bio SB Inc. (U.S.).